TOMTOM
25.10.2016 07:32:28 CEST | Business Wire | Press release
Marking a significant milestone for its Consumer business, TomTom (TOM2 ) today announces a major advertising campaign supporting TomTom Sports: Get Going . The campaign reinforces TomTom’s commitment to continue to launch Sports Wearables that inspire people to move. Created in partnership with Amsterdam-based agency Pool Worldwide, the campaign spans global markets with television, cinema, print, digital and out of home ad placements.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161024006174/en/
“Since 2011 we’ve set out to create Sports products that inspire people to move by taking away barriers and celebrating achievements. We were the first to integrate an optical Heart-Rate monitor into a GPS running watch and by integrating a music player we empowered people to leave increasingly larger and heavier phones at home. We have recently launched the world’s first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist – answering the age-old question ‘is what I’m doing, doing anything for me’. Today we’re incredibly proud to launch the Get Going campaign to further strengthen the TomTom Sports brand.” said Corinne Vigreux, Co-Founder and Managing Director, TomTom Consumer.
Patrick Stal, VP of Marketing for TomTom Sports adds: “This campaign marks a milestone for our brand. It showcases a TomTom Sports brand that caters to the needs of audiences ranging from those that are taking their first step down the road, to those that are stepping over the starting line of their first marathon. We are claiming a unique space in the world of sports. TomTom Sports is not here to shout at you to beat the impossible, be unstoppable, go harder, tougher, longer, deeper, rougher or sweatier. Let other sports brands do that. We want to help people where they need it most. Right at the beginning, where excuses often beat conviction. We want to be the brand that inspires people to Get Going and take that first step, no matter how big or small their effort might be, time and time again.”
For more information, visit http://getgoing.tomtom.com/en_gb .
Watch the hero ad here .
Credits:
End responsible at TomTom: Patrick Stal, Kelly McConville
Concept: Pool Worldwide
Creative Strategy: Pool Worldwide
Account: Pool Worldwide
RTV Producer: Sio van Bochove
Production Company: Pool Worldwide
Director: Paul Meijer
Producer: Sio van Bochove
Editor: Robert van Ees
Post production: The Ambassadors
Sound studio: The Ambassadors
-ENDS-
About TomTom Sports
TomTom Sports is on a mission to help you get going.
Since 2011, we’ve developed Sports and Fitness products that make it easier to get moving.
We were the first to add an optical heart-rate monitor to a GPS Sports Watch with TomTom Cardio , and by integrating a music player into our Sports Watches have enabled you to leave your smartphone at home. We’ve always been focused on innovating to make it easier to get going.
We also recently launched TomTom Touch , the first fitness tracker that combines body composition analysis with steps, sleep and all day heart-rate tracking, right from the wrist, technology usually reserved for elite athletes.
Find the full TomTom Sports product lineup here .
About TomTom
At TomTom (TOM2) our mission is to make technology so easy to use, that everyone can achieve more.
We created easy to use navigation devices, helping millions of people to get where they want to be. Today, we continue to simplify the complex, making technology more accessible for everyone.
We serve four different markets: Consumer, Telematics, Automotive and Licensing.
We make easy to use navigation devices, sport watches and action cameras for consumers. We enable businesses with vehicles to more easily manage and improve fleet efficiency whilst increasing overall business performance with our Telematics solutions. We also offer a world leading real-time map platform that is powering innovative location based services and helping to make automated driving a reality for the automotive industry.
Founded in 1991 and headquartered in Amsterdam, we have over 4,600 employees and sell our products worldwide.
View source version on businesswire.com: http://www.businesswire.com/news/home/20161024006174/en/
Contact:
TomTom
Media
Lindsay Mandeville
+31 6 11
334292
lindsay.mandeville@tomtom.com
or
Investor
Relations
Bisera Grubesic
+31 20 75 75 194
ir@tomtom.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom